文献速递前列腺癌

使用5α-还原酶抑制剂者的前列腺癌筛查结局

Outcomes of Prostate Cancer Screening by 5α-Reductase Inhibitor Use.
PubMed 文献 · J Urol · 2017-02-16

在FinRSPC随机试验中,评估使用5α-还原酶抑制剂(5-ARI)男性的前列腺癌筛查结局。使用5-ARI者中位PSA更高、筛查阳性更常见,但筛查未显著影响前列腺癌检出(HR 0.89,95%CI 0.79-1.01)或死亡率(HR 0.82,95%CI 0.51-1.32)。ROC分析中5-ARI使用者PSA和年龄预测Gleason 7-10前列腺癌的准确性低于非使用者(首轮筛查AUC 0.79 vs 0.88)。

要点

  • 使用5-ARI的男性中位PSA更高,且更常筛查阳性。
  • 使用5-ARI的男性中,筛查未显著影响前列腺癌检出(HR 0.89,95%CI 0.79-1.01)。
  • 使用5-ARI的男性中,筛查未显著影响前列腺癌死亡率(HR 0.82,95%CI 0.51-1.32)。

核心结论

  • 在接受5-ARI的男性中,基于PSA的筛查未改善高级别或转移性前列腺癌的检出,也未预防前列腺癌死亡。

研究设计与样本

  • 研究在FinRSPC(芬兰前列腺癌筛查随机研究)中开展,80,454名男性中31,866名随机分配至1996至2004年间每4年筛查一次。
  • 从国家处方数据库收集78,615名男性1995至2009年前列腺癌诊断前5-ARI报销信息,使用Cox回归评估5-ARI对筛查与前列腺癌风险及死亡率关系的影响。

主要发现

  • 接受5-ARI的男性中位PSA更高,且较非使用者更常筛查阳性。
  • 在5-ARI使用者中,筛查组与对照组相比前列腺癌检出无显著差异(HR 0.89,95%CI 0.79-1.01)。
  • 在5-ARI使用者中,筛查组与对照组相比前列腺癌死亡率无显著差异(HR 0.82,95%CI 0.51-1.32)。
  • ROC分析中,5-ARI使用者首轮筛查PSA和年龄预测Gleason 7-10前列腺癌的AUC为0.79,非使用者为0.88。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Prostate cancer screening with prostate specific antigen reduces prostate cancer mortality but leads to over diagnosis of indolent prostate cancer. The use of 5α-reductase inhibitors lowers prostate specific antigen and in theory could affect the performance of prostate specific antigen based screening. We evaluated the outcomes of prostate cancer screening in 5α-reductase inhibitors users. MATERIALS AND METHODS: The study was performed in FinRSPC (Finnish Randomized Study of Screening for Prostate Cancer). Of 80,454 men 31,866 were randomized to be screened at 4-year intervals during 1996 to 2004. Information on 5α-reductase inhibitors reimbursements before prostate cancer during 1995 to 2009 was collected from the national prescription database for 78,615 men. We evaluated the effect of screening on prostate cancer risk and mortality by 5α-reductase inhibitors using Cox regression. RESULTS: Men receiving 5α-reductase inhibitors had higher median prostate specific antigen and were more often screen positive than nonusers. Despite this, screening did not significantly affect prostate cancer detection (HR 0.89, 95% CI 0.79-1.01) or mortality (HR 0.82, 95% CI 0.51-1.32) compared to findings in the control arm among men on 5α-reductase inhibitors. On ROC analysis prostate specific antigen and age did not predict Gleason 7-10 prostate cancer as accurately in 5α-reductase inhibitors users as it did among nonusers (first screening round AUC 0.79 vs 0.88). CONCLUSIONS: Prostate specific antigen based screening among men receiving 5α-reductase inhibitors did not improve the detection of high grade or metastatic prostate cancer, or prevent prostate cancer death.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Murtola TJ, Virkku A, Talala K, et al. Outcomes of Prostate Cancer Screening by 5α-Reductase Inhibitor Use. J Urol. 2017. PMID: 28216328. doi:10.1016/j.juro.2017.02.069

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。